Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research report issued on Thursday. The brokerage set a “buy” rating on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the stock. Guggenheim cut their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, November 15th. HC Wainwright cut their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, Mizuho cut their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $2.79.

Adaptimmune Therapeutics Trading Up 3.3 %

NASDAQ:ADAP opened at $0.46 on Thursday. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 12 month low of $0.44 and a 12 month high of $1.70. The company has a market cap of $118.14 million, a PE ratio of -2.10 and a beta of 2.52. The company has a 50 day simple moving average of $0.57 and a two-hundred day simple moving average of $0.74.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of hedge funds have recently modified their holdings of the business. Two Seas Capital LP bought a new stake in shares of Adaptimmune Therapeutics during the 4th quarter valued at $7,992,000. Two Sigma Investments LP grew its position in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 19,146 shares during the period. Two Sigma Advisers LP grew its position in shares of Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 58,787 shares during the period. Jane Street Group LLC grew its position in shares of Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock valued at $176,000 after acquiring an additional 152,780 shares during the period. Finally, Long Focus Capital Management LLC grew its position in shares of Adaptimmune Therapeutics by 54.1% during the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock valued at $11,040,000 after acquiring an additional 7,194,503 shares during the period. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.